The need for airway clearance is not disease-specific, but may arise from a variety of risk factors that impair normal secretion clearance:
- Recurrent respiratory infections
- Respiratory muscle weakness
- Mucus plugging and atelectasis
- Increased difficulty in breathing
- Hyper production of secretions
- More frequent tightness in the chest
- Abnormally thick, sticky secretions
- Ineffective cough
RespIn 11 benefits from a totally new innovative approach to the 30-year-old concept of High Frequency Chest Wall Oscillation/Chest Compression therapy.
‘Focused pulse’ used in Respin 11* transfers only 10% of the energy to the patient that High Frequency Chest Compression devices or HFCWO therapy devices do.
This means for the patient that they only need to be able to tolerate 1/10th of the energy that existing devices on the market today deliver.
- Therapeutic pulsations directly to targeted areas
- Independent treatment areas
- No negative physiological side effects
- Creates 4-5 times greater lungs movement
- Very low background pressure
- Improved therapy compliance
- Wide range of patients and ages.
The RespIn 11 uses an innovative patented system of ‘focused pulse’ technology incorporating a system of proprietary valves, pressure pistons and electronic controls which deliver therapeutic pulsations directly to targeted areas of the patient’s thorax - exactly where most required and most beneficial in the treating clinician’s view.
- 4 preset protocols
- Can store up to 3 Customer therapies
- Pads and wraps size range
- Pads for bedridden patients
- Easy to use
- User-friendly display.
* temporarily not available in Russia